Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients

Basak, Edwin A.; Meer, Jan W M van der; Hurkmans, Daan P.; Schreurs, Marco W. J.; Hoop, Esther Oomen–de; Veldt, Astrid A.M. van der; Bins, Sander; Joosse, Arjen; Koolen, Stijn L.W.; Debets, Reno; Peeters, Robin P.; Aerts, Joachim; Mathijssen, Ron H.J.; Medici, Marco

doi:10.1089/thy.2019.0726

Cited by 62 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased risk in the incidence of colorectal and thyroid carcinoma as well as increased cancer mortality has been reported in individuals with subclinical hypothyroidism [ 114 ]. Recently, overt thyroid dysfunction has been found to predict response to anti-PD-1 immunotherapy in association with anti-thyroid antibodies and is of clinical relevance for overall patient survival of non-small-cell lung carcinoma patients [ 115 ]. In recent times, a strong association between primary malignancies of thyroid and melanoma has been established [ 116 ].…”

Section: Disorders and Diseases Associated With Thyroid Dysfunctionmentioning

confidence: 99%

Prospective role of thyroid disorders in monitoring COVID-19 pandemic

Kumari

Chainy

Subudhi

2020

Heliyon

View full text Add to dashboard Cite

Section: Disorders and Diseases Associated With Thyroid Dysfunctionmentioning

confidence: 99%

Prospective role of thyroid disorders in monitoring COVID-19 pandemic

Kumari

Chainy

Subudhi

2020

Heliyon

View full text Add to dashboard Cite

“…Thyroid dysfunction is a common pathological state of thyroid hormone disorder, most commonly hypothyroidism ( 15 ). It needs active surveillance and treatment; otherwise, severe thyroid dysfunction may seriously affect health in some cases ( 16 , 17 ). The specific mechanism of hypothyroidism is still unclear and warrants further laboratory and clinical exploration.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management

et al. 2021

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are a group of drugs employed in the treatment of various types of malignant tumors and improve the therapeutic effect. ICIs blocks negative co-stimulatory molecules, such as programmed cell death gene-1 (PD-1) and its ligand (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), reactivating the recognition and killing effect of the immune system on tumors. However, the reactivation of the immune system can also lead to the death of normal organs, tissues, and cells, eventually leading to immune-related adverse events (IRAEs). IRAEs involve various organs and tissues and also cause thyroid dysfunction. This article reviews the epidemiology, clinical manifestations, possible pathogenesis, and management of ICIs-related thyroid dysfunction.

show abstract

“…Some clinical studies have found that thyroid dysfunction may occur after use of PD-1/PD-L1 inhibitor [6] .…”

Section: Introductionmentioning

confidence: 99%

“…Compared with the normal population, HT patients have a higher probability of developing TC, but its pathogenesis remains unclear [5] . Some clinical studies have found that thyroid dysfunction may occur after use of PD-1/PD-L1 inhibitor [6] .…”

Section: Introductionmentioning

confidence: 99%

T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis

Zhu

Dai

Ruan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The incidence of papillary thyroid carcinoma (PTC) has been steadily increasing over the past decades. Hashimoto’s thyroiditis (HT) is the most common autoimmune disease, and is related to the pathogenesis of PTC. Programmed cell death protein-1 (PD-1) is currently used for the treatment of PTC, but there are very few studies on the clinical value of PD-1 in the diagnosis and targeted therapy of PTC. Methods The expressions of PD-1 in the peripheral blood of 139 patients with PTC (PTC group), 48 patients with thyroid nodules (TN group) and 63 healthy subjects (HP group) were detected by flow cytometry. The expressions of plasma T3, T4, FT3, FT4, TSH, TGAb and TPO were detected by chemiluminescence immunoassay. T cell subsets, thyroid function indexes and PD-1 were also detected. Results The expressions of FT3, TGAb, CD3+PD-1+, CD3+CD4+PD-1+ and CD3+CD8+PD-1+ in PTC and TN were significantly higher than that in the HP group. Moreover, CD3+PD-1+, CD3+CD4+PD-1+ and CD3+CD8+PD-1+ expressions had significant differences between the PTC group and the TN group. In addition, the expressions of TGAb, TPO, CD3+PD-1+, CD3+CD4+PD-1+ and CD3+CD8+PD-1+ in PTC combined with HT (PCH group) were significantly higher than that in the PTC group. PD-1 showed a significant correlation with PTC lymph node metastasis. CD3+PD-1+ and CD3+CD4+PD-1+ expressions were higher in N1 stage than in N0 stage. Conclusions The present study showed that T cell exhaustion might act as a biomarker for the differential diagnosis of PTC and TN. The combination of PD-1, TGAb and TPO might be used as an early warning biomarker for the progression of HT to PTC. Targeting the PD-1 pathway could be a new approach to treat PTC and prevent malignant transformation from HT to PCH in the future.

show abstract

Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients

Cited by 62 publications

References 27 publications

Prospective role of thyroid disorders in monitoring COVID-19 pandemic

Prospective role of thyroid disorders in monitoring COVID-19 pandemic

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management

T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis

Contact Info

Product

Resources

About